Name: POLYPID LTD (PYPD) Stock
Brand: POLYPID LTD
Rating: 6 (3 reviews)

PYPD Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: PolyPid Ltd.

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

a month ago - By: PolyPid Ltd.

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

2 months ago - By: PolyPid Ltd.

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

2 months ago - By: PolyPid Ltd.

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

6 months ago - By: Benzinga

A Look Ahead: PolyPid's Earnings Forecast

10 months ago - By: Benzinga - Mentions: AVXL KMPR ACVA

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

2 months ago - By: PolyPid Ltd.

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

2 months ago - By: PolyPid Ltd.

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

3 months ago - By: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: PolyPid Ltd.

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

3 months ago - By: PolyPid Ltd.

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

5 months ago - By: Yahoo Finance - Mentions: SKYE

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

5 months ago - By: PolyPid Ltd.

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

5 months ago - By: PolyPid Ltd.

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

5 months ago - By: PolyPid Ltd.

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

6 months ago - By: PolyPid Ltd.

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

6 months ago - By: PolyPid Ltd.

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

8 months ago - By: ACCESS Newswire - Mentions: DRTS GIFT VOXR FEMY ...

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

8 months ago - By: ACCESS Newswire

PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025

9 months ago - By: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

9 months ago - By: PolyPid Ltd.

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

9 months ago - By: PolyPid Ltd.

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

11 months ago - By: PolyPid Ltd.

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

a year ago - By: PolyPid Ltd.

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

a year ago - By: PolyPid Ltd.

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

a year ago - By: PolyPid Ltd.

POLYPID LTD (PYPD) Stock News

PYPD Latest News, Press Relases and Analysis

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

A Look Ahead: PolyPid's Earnings Forecast

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results